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Protein folding, misfolding and diseaseIt has been inspiring to act as guest editor for FEBS Letters and
to bring together some of the leading researchers within the ﬁeld
of protein folding, misfolding and disease. I am grateful to all con-
tributors, reviewers and to the editor Peter Brzezinski for working
with me on this issue.
Protein aggregation was for decades regarded as a mere
nuisance in protein research. This process often occurred after a
tedious isolation procedure for functional studies and in
concentrated protein solutions used for setting up crystallization
screens. Just as frustrating were the early days of protein folding.
Scientists were equally frustrated in detecting a turbid sample in
the dialysis bag when returning to the lab in the early morning
hours as to ﬁnd that their refolded protein sample lacked speciﬁc
activity or turned opalescent during rapid dilution of a
chemically denatured protein in the stopped ﬂow machine or dur-
ing thermal denaturation. Few researchers at the time realized that
the misfolded states of proteins would hold the key to some of the
most severely debilitating diseases known to man.
With the discovery of molecular chaperones in the 1980s and
their essentiality in cellular homeostasis things started to change.
In the medical community, the discovery of insoluble protein
deposits as pathognomonic hallmarks in various human diseases
made researchers and pathologists realize that there was more to
this than mere coincidence.
The literature today is ﬁlled with exciting descriptions of mis-
folded proteins. There is no doubt that the human sufferings from
misfolding diseases are grave, but at the same time researchers in
the ﬁeld are awestruck by the beauty of the formed self-assembled
ﬁbrillar structures. Moreover it is astonishing how well orches-
trated the cellular machinery is that prevents these aberrant struc-
tures to form and facilitates misfolded protein degradation. The
most amazing quality of protein folding is that it actually works
at all; rendering functional proteins, despite the complex crowded
environment of the cell and in the surrounding hostile environ-
ment of the extracellular space.
In this FEBS Letters Special Issue on Protein Folding, Misfolding
and Disease a number of leading researchers in the ﬁeld discuss
several important avenues for understanding these diseases on a
molecular level; as well as new methods for following these pro-
cesses in real time, using new technologies, at increasing molecular
detail.
The issue starts with an overview from Luheshi and Dobson
describing new methods to study amyloid ﬁbril formation; both
in simple organisms and in the test tube. New interesting methods
are particularly highlighted in the following three contributions.
First, the article by Knowles and co-workers describes label free
quantitative methods for studying amyloid ﬁbril formation. The
methodological section is followed by a review on new and exist-
ing ﬂuorescent molecular probes for amyloid structure and process0014-5793/$ - see front matter  2009 Federation of European Biochemical Societies. P
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chemical and physical properties as attractive alternatives to the
dominant molecular reporter probe in the ﬁeld, Thioﬂavin T. Lang-
kilde and Vestergaard then provide an overview of structural
methods for characterization of amyloid ﬁbrils and preﬁbrillar
intermediates including small-angle scattering methods that can
produce reasonably high-resolution structures in solution during
the ﬁbril formation process.
Riek and co-workers present an overview of high-resolution
structural studies of amyloid ﬁbrils and provide a stimulating anal-
ysis of these intriguing structures at atomic resolution. They also
discuss toxic versus infectious and functional ﬁbril folds. Baskakov
examines the distinction between catalytic and templating prop-
erty of amyloid ﬁbrils and illustrates that conformational switch-
ing within individual ﬁbrils are indeed possible on a rugged
energy surface. Platt and Radford discuss the current molecular
understanding of the dialysis-related amyloidogenic protein b2-
microglobulin and describe distinct roles of individual residues in
the misfolding process. Next, Bemporad and Chiti show the mech-
anism of native-like state intermolecular recognition that induces
aggregation as a starting point for amyloid ﬁbril formation. The
authors discuss the possible generality of this hitherto rather unu-
sual initiation process which so far has been restricted to the
serpinopathies.
Our cells are well equipped to handle protein folding and mis-
folding. Balch and co-workers provide an overview of how our cells
handle the proteostasis balance and how subtle changes in this
balance can drastically increase the risk for disease. It is likely that
a similar shift in the opposite direction could also provide a thera-
peutic intervention. The Balch systemic view of the proteostasis
machinery is followed by a review by Broadly and Hartl discussing
how the molecular chaperones Hsp70/Hsp40 and TriC handle
aggregation prone proteins. Horwich and co-workers discuss the ﬁ-
nal steps of the GroEL/ES assisted folding process and how the
GroEL/ES cis-cavity functions as a fascinating nano-capsule that
prevents aggregation and provides a safe haven for the substrate
protein during folding.
Joel Buxbaum invites the reader into the realm of mouse models
– by far the dominating organism for disease modeling in the amy-
loidoses and prionoses. Buxbaum discusses both the pros and cons
of murine models of several human misfolding diseases.
Nuvolone, Aguzzi and Heikenwalder provide insight into the
current understanding of how mammalian cells are colonized by
infectious prions and facilitate their replication.
Gunilla and Per Westermark show the captivating phenomena
behind the systemic AA amyloidosis, and how this system behaves
like a prionoid (prion-like amyloidosis), probably through extre-
mely efﬁcient replication of the AA amyloid ﬁbril fold at elevated
SAA serum concentrations.ublished by Elsevier B.V. All rights reserved.
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for new, possibly general, degradation pathways of misfolded pro-
teins by the plasma proteases tPA and FXII, previously only thought
to be involved haemostatic control of ﬁbrinolysis and contact sys-
tem activation of blood coagulation. Their hypothesis states that
these are natural ancient protective systems of ‘‘garbage disposal”
and also provides further insight into the proteostasis machinery;
which under the correct circumstances keeps our blood stream
clear from aggregated protein.
We, as a community, still stand short in delivering a benign dis-
ease-modifying treatment or cure to any of the misfolding dis-
eases. The basics of protein folding and misfolding are still not
fully appreciated and our current understanding of amyloidoses
and prionoses will likely prove to be the tip of the iceberg. It is
our hope that this special issue on Protein Folding, Misfolding
and Disease, which provides personal and somewhat provocative
views from the contributing authors, will stimulate further re-search within this ﬁeld. The idea is that this issue should both sum-
marize the vast amount of literature on the subject as well as
inspire current and future researchers within the ﬁeld, in order
to understand the fascinating underpinning biology of protein fold-
ing and misfolding. Ultimately the research summarized within
this special issue will, with a bit of luck, assist in deciphering the
pathology behind horriﬁc human diseases and facilitate the devel-
opment of a much needed disease-modifying treatment in the not
too distant future.
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